Zydus Lifesciences Limited
ZYDUSLIFE · Pharma · NSE
₹937
Current Market Price
Fair Value (DCF)
₹1,384
Margin of Safety
+47.7%
Updated 9h ago
YieldIQ Score
45/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
33%
ROE
17.2%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.94 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
21.7%
Return on capital employed
EV / EBITDA
13.1×
Enterprise multiple
Debt / EBITDA
0.4×
Leverage vs earnings
Interest Coverage
65.5×
EBIT covers interest
Current Ratio
1.89×
Short-term liquidity
Asset Turnover
0.66×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
10.3%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹937.1
Bear case
₹824.42
MoS -13.7%
Base case
₹1,383.92
MoS +32.3%
Bull case
₹1,894.79
MoS +50.5%
Ratio Trends
ZYDUSLIFE · last 4 annual periods
ROE
17.2%
ROCE
23.8%
Operating Margin
—
Debt / Equity
0.12×
PE
25.2×
EV / EBITDA
14.6×
Historical Financials
ZYDUSLIFE · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹15.1K Cr | ₹15.3K Cr | ₹5011 Cr | ₹5534 Cr | ₹22.6K Cr | +10.6% |
| EBITDA | — | ₹3689 Cr | ₹3438 Cr | ₹5617 Cr | ₹7036 Cr | +17.5% |
| EBIT | ₹2448 Cr | ₹2965 Cr | ₹514 Cr | ₹1582 Cr | — | -10.3% |
| PAT | ₹2185 Cr | ₹4618 Cr | ₹358 Cr | ₹1246 Cr | ₹4526 Cr | +20.0% |
| EPS (diluted) | ₹20.84 | ₹21.90 | ₹2.95 | ₹11.66 | — | -13.5% |
| CFO | ₹3293 Cr | ₹2078 Cr | ₹2689 Cr | ₹3228 Cr | ₹6777 Cr | +19.8% |
| CapEx | — | — | — | — | ₹-1713 Cr | — |
| FCF | — | — | — | — | ₹5064 Cr | +0.0% |
| Total Assets | — | ₹27.8K Cr | ₹25.8K Cr | ₹29.3K Cr | ₹37.2K Cr | +7.6% |
| Total Debt | — | — | ₹1163 Cr | ₹769 Cr | ₹3213 Cr | +28.9% |
| Shareholders' Equity | — | — | ₹17.5K Cr | ₹19.8K Cr | ₹26.4K Cr | +10.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ZYDUSLIFE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| CIPLA Cipla Limited | +43.1% | 66 | Data Limited | 16.9% | 22.1× |
| MANKIND Mankind Pharma Limited | -38.3% | 40 | Overvalued | 13.7% | — |
| DRREDDY Dr. Reddy's Laboratories Limited | +73.3% | 63 | Undervalued | 16.8% | 16.8× |
| LUPIN Lupin Limited | +16.1% | 37 | Undervalued | 19.0% | — |
| AUROPHARMA Aurobindo Pharma Limited | +36.3% | 59 | Undervalued | 10.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
9 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹26.00/sh
Last payout
2025-07-25
₹11.00
Peak payout
₹11.00
Trailing yield
1.17%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ZYDUSLIFE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ZYDUSLIFE →
Compare
Head-to-head with peers
Compare ZYDUSLIFE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ZYDUSLIFENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.